Clinical Trials
23 trialsNCT02696993 2026-05-20
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06712927 2026-05-18
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT05012254 2026-05-05
NIVIPI-Brain
FundaciĆ³n GECP
Phase 2 Active not recruiting
NCT05341349 2026-04-23
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Terminated
NCT04817254 2026-04-17
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05048212 2026-04-09
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07134842 2026-04-09
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT04511013 2025-09-11
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
Phase 2 Recruiting
NCT01703507 2025-05-16
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Thomas Jefferson University
Phase 1 Completed
NCT02107755 2024-05-21
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT02115139 2022-11-08
GRAY-B
Grupo EspaƱol Multidisciplinar de Melanoma
Phase 2 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT02097732 2021-05-12
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03728465 2021-02-03
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
University Hospital Tuebingen
Phase 2 Terminated
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02662725 2016-01-25
IPI+RTS
University Hospital, Lille
Phase 2 Completed
NCT02460068 2015-06-02
NIBIT-M2
Italian Network for Tumor Biotherapy Foundation
Phase 3 Unknown